Call for Abstract

27th Cancer Genomics Congress: New Era for Cancer Prevention , will be organized around the theme “Integrating every bit of cancer prevention & Exploring the Possibilities in Cancer Genomics ”

Cancer Genomics 2020 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in Cancer Genomics 2020

Submit your abstract to any of the mentioned tracks.

Register now for the conference by choosing an appropriate package suitable to you.

Cancer could be a cluster of diseases caused by changes in DNA that alter cell behavior, causing uncontrollable growth and malignancy. Genomics is that the study of the sequence of those letters in your DNA and the way every string of letters passes data to assist every cell in your body work properly. Cancer genetics aims beneath stand to know to grasp the genetic basis of tumor cell proliferation and also the evolution of the cancer ordination under mutation and selection by the body surroundings, the system and therapeutic interventions.

 

  • Track 1-1Tumor evolution and changes in genomic heterogeneity
  • Track 1-2Liquid biopsy
  • Track 1-3Immunogenomics
  • Track 1-4Future forward

 

<p style="\&quot;text-align:" justify;\"="">Cancer epigenomic analysis is driven by the advancement of novel innovations and also the usage of model living beings running from yeasts to plants to vertebrates. For quite and very long time, the seek for malignant growth qualities has focused on hereditary defects that were used as labels for identification of those qualities. With the acknowledgment that epigenetic changes, especially DNA methylation events, are engaged with transcriptional changes in each tumour suppressor genes and oncogenes, strategies are created that facilitate the identification of novel malignancy genes changed by DNA methylation alone or in combine with hereditary events. Metagenomics is another horizon in cancer research. Metagenomics has widened the extent of focusing on organisms in charge of inciting totally different sorts of diseases. About 16.1% of malignant growths are connected with microbic disease. Metagenomics is Associate in nursing just technique for recognizing and concentrate micro-organisms within their surroundings.

  • Track 2-1Tumor Genomes
  • Track 2-2Tumor Epigenomes

 

<p style="\&quot;text-align:" justify;\"="">Cancer immunogenomics initially was encircled by research supporting the speculation that cancer mutations created novel peptides seen as "non-self" by the system. The scan for these "neoantigens" has been encouraged by the mixture of recent sequencing innovations, specific machine examinations, and HLA binding forecasts that assess physical changes in an exceedingly cancer ordination and decipher their capability to make a resistant stimulatory peptide. The next knowledge will portray a tumor's neoantigen stack, its unit of penetrating resistant cell varieties, the T or lymphocyte receptor assortment, and direct the structure of a custom-built therapeutic.

  • Track 3-1Tumor Evolution and Immune Selection
  • Track 3-2Antigen Presentation
  • Track 3-3 Immune Activation and Exhaustion
  • Track 3-4 Genomic Sequencing
  • Track 3-5High-Throughput Tumor Antigen Screening
  • Track 3-6Gene Expression

 

<p justify;\"="" style="text-align: justify;">Mutations for hereditary cancer syndromes are at high hazard for the advancement of tumours at associate degree early age and additionally the synchronous or metachronous improvement of various tumors of the relating tumor spectrum. The hereditary reasons for a few inherited disease disorders have simply been distinguished. Regarding 5-hitter of all diseases is a locality of associate degree transmissible malignant growth disorder. Clinical criteria are as of now accessible as per that varied innate cancer syndromes is analyzed or suspected and that indicate the means more molecular genetic analysis. A doctor will simply decide if these criteria ar met by coordinated addressing about the patient's personal and family healthful history. The recognizable proof of the causative germ line modification within the family permits affirmation of the conclusion within the influenced individual and opens up the choice of prescient testing in healthy relatives.

  • Track 4-1Hereditary Breast & Ovarian Cancer Syndrome
  • Track 4-2Cowden Syndrome
  • Track 4-3Hereditary Non-polyposis Colorectal Cancer Syndrome
  • Track 4-4Familial Adenomatous Polyposis
  • Track 4-5Li-Fraumeni Syndrome

Identification of genomic modifications has given the perfect element to infer new procedures for molecular primarily based precision drugs of adult and paediatric cancers together with risk evaluation, non-invasive detection, and molecular diagnosis and customized treatment. Additionally, it's presently obvious that the spectra of genomic-based changes and systems in paediatric malignancies aren't quite identical as those dominatingly happening in adult cancers. Adult Cancers on the average show generously higher alteration weights compared with the childhood tumors. Collecting proof likewise recommends that the kind of genomic changes usually experienced in adult cancer isn't quite identical as those saw in paediatric malignancies.

  • Track 5-1 Cancer genomics of adult and pediatric solid tumors
  • Track 5-2Mutation signatures
  • Track 5-3 Single nucleotide variants (SNVs) and small insertions/deletions
  • Track 5-4 Copy number alterations
  • Track 5-5Structural changes (gene fusions and chromosomal rearrangements)
  • Track 5-6The epigenome and epigenetic modifiers

 

<p about="" alone="" among="" and="" assorted="" biology="" cancer="" carry="" chemical="" communications="" data="" difficulties="" disciplines="" for="" from="" fundamental="" growth.="" helpfully="" in="" individual="" is="" malignancy="" malignant="" material="" methodically="" n="" novel="" of="" or="" originate="" p="" perceives="" prompt="" sector="" sent="" software="" text-align:"="" system="" systems="" that="" the="" think="" to="" types="" up="" upset="" variety="" various="" ways="" which="" who="" will="" within="" style="text-align: justify;">Cancer systems biology represents the applying of systems biology approaches to upset the investigation of however the animate thing networks of typical cells are disturbed during carcinogenesis to create viable predictive models which will facilitate researchers and clinicians within the approvals of recent treatments and medications. These annoyances are caused by the massive and progressing genomic and epigenetic instability in tumors adjusting the elements of wide range of molecules and systems during a cell and additional entangled by the changes within the interactions with the native surroundings and additionally the individual as a full through the tumorigenic method itself. Cancer systems biology approaches are thus dependent on the employment of computational and numerical techniques to decipher the multifaceted nature in cancer heterogeneity.

  • Track 6-1Systems approaches for cell heterogeneity
  • Track 6-2Systems approaches for targeted therapy
  • Track 6-3 Approaches for drug resistance
  • Track 6-4 Data sharing

Structural genomics may be a field of genomics that features the portrayal of genome structures. This information is useful within the act of dominant the genes and DNA parts of a species. Basic genetics depicts the three-dimensional structure of each last supermolecule which may be encoded by a genome - once significantly dissecting proteins; this can be additional unremarkably noted as structural genetic science. The examination is anticipated to speculate the structure of the total ordering, by victimization each experimental and process ways. Whereas standard structural prediction centers on the structure of a selected protein being noted, genomics considers a much bigger scale by expecting to decide the structure of every constituent protein encoded by a genome.

  • Track 7-1Drug Discovery Technologies
  • Track 7-2Structural Genomics
  • Track 7-3 Fragment-Based Drug Design
  • Track 7-4Strategy and Drug Research
  • Track 7-5 Proteins and Protein Structure
  • Track 7-6Structural Genomics and Proteomics

Numerous genetic and epigenetic events reveal tumor progression and outline the characteristics of tumors. Advances in high-throughput technologies, similar to gene expression profiling, next-generation sequencing, proteomics, and metabolomics, have authorized detailed molecular characterization of various tumors. The coordination and investigations of the high-throughput info have straight various novel molecular variations and network alterations in tumors. These molecular changes incorporate different malignant growth driving transformations, gene fusions, amplification, deletion, and post-translational modifications, among others. An outsized range of those genomic events ar being utilised in cancer diagnosis, though others are remedially centered on small-molecule inhibitors. Various genes/catalysts that play a task in DNA and histone modifications are to boot changed in several cancers, dynamic the epigenomic landscape amid malignant growth initiation and progression. Except for protein-coding genes, studies are revealing the basic body roles compete by noncoding RNAs and noncoding regions of the ordering throughout malignancy progression. A substantial lot of those genomic and epigenetic events tandem to drive tumor improvement and metastasis. simultaneous advances in genome-regulating innovations, kind of like factor silencing and ordering piece of writing, are providing the capability to understand very well the procedure of malignancy initiation, movement, and motioning and additionally opening up roads for therapeutic targeting.

  • Track 8-1Gene Mutations
  • Track 8-2 Common Genomic and Epigenomic Alterations in Cancer
  • Track 8-3 Genetic and Epigenetic Diagnosis in Cancer
  • Track 8-4 Noncoding RNAs in Cancer

Biomarkers are molecules that indicate traditional or abnormal technique happening in your body and may be an indication of associate underlying condition or sickness. Various types of molecules, like DNA (genes), proteins or hormones, will function as biomarkers, since all of them indicate one issue relating to your health. Biomarkers also are created by the cancer tissue itself or by completely different cells inside the body in response to cancer. They will be found inside the blood, stool, urine, tumor tissue, or completely different tissues or bodily fluids. Notably, biomarkers don't seem to be restricted to cancer. There are biomarkers for cardiopathy, disseminated sclerosis, and many of various diseases.

  • Track 9-1Biomarkers in cancer care
  • Track 9-2 Processes of biomarker development
  • Track 9-3Biomarker discovery
  • Track 9-4 Biomarker assay development and analytical validation
  • Track 9-5Validation of clinical utility

Individuals that inherit genomic mutation from their parents are at a bigger risk of certain varieties of cancers. Familial cancer syndromes are the group of cancers wherever patients inherit genomes that don't perform properly, increasing the chance of developing cancer.

Approximately 100 familial cancer syndromes are known and this vary is growing. The genes identified as increasing the chance of cancer are usually chromosome dominant (only one amongst the try of body’s must have the mutation so as for it to be expressed) though they'll even be chromosome recessive (both chromosomes ought to have the mutation for it to be expressed). The identification of these genes has improved designation and helped verify new cancer treatments.

The growing use of biological therapies that have an effect on cellular signal pathways has revolutionized the treatment of cancer, a trend which will continue as treatment ways in which could also be personalized to people once genomic typing of their cancer is known.

  • Track 10-1Biological pathways in genetic cancers
  • Track 10-2Breast and ovarian cancer
  • Track 10-3Renal cancer
  • Track 10-4Bowel cancer
  • Track 10-5Prostate cancer
  • Track 10-6Multiple endocrine neoplasia 1 and 2
  • Track 10-7Retinoblastoma
  • Track 10-8MicroRNA and cancer